Please login to the form below

Not currently logged in

Keytruda bounces back in rivalry with Opdivo

First drug in its class to secure FDA approval as a first-line therapy for malignant melanoma

Merck & Co headquartersMerck & Co has reported two important pieces of news that could lend momentum to its PD-1 inhibitor Keytruda as it vies for market share with rival Opdivo from Bristol-Myers Squibb.

In the last few days, Keytruda (pembrolizumab) has become the first drug in its class to secure FDA approval as a first-line therapy for malignant melanoma, regardless of BRAF status, and has also shown impressive survival data compared to chemotherapy in lung cancer.

The first-line approval in melanoma gives the drug an edge over Opdivo (nivolumab), which was approved by the US regulator in November for use only in previously-untreated melanoma patients with BRAF wild-type tumours. BMS also filed for approval of BRAF V600-positive melanoma but had its application turned down by the FDA with a request for more data. 

The frontline approval is based on a substantial improvement in progression-free (PFS) and overall survival (OS) compared with BMS' older immuno-oncology drug Yervoy (ipilimumab) in the phase III KEYNOTE-006 trial. 

The FDA has also updated the label for Keytruda to include the treatment of patients with Yervoy-refractory melanoma on the strength of another trial - KEYNOTE-002 - which found a 43% reduction in the risk of death compared to chemotherapy in this indication.

Survival data in PD-L1-positive NSCLC

Meanwhile, Keytruda significantly improved overall survival (OS) in the KEYNOTE-010 trial, becoming the first cancer immunotherapy to best chemotherapy on this measure in patients whose tumours express the PD-L1 protein.

The results reveal that two doses of the antibody - the approved 2 mg/kg dose and an investigational 10 mg/kg dose - improved median survival in PD-L1-positive patients by 29% compared with docetaxel. The benefit was even greater in the group of patients with PD-L1 staining in more than 50% of tumour cells.

Among the patients with high PD-L1 expression, the lower dose of Keytruda was associated with an OS of 14.9 months, compared to just over eight months with docetaxel. Raising the dose to 10 mg/kg extended OS to more than 17 months.

The FDA granted accelerated approval to Keytruda for previously-treated patients with NSCLC whose tumours show 50% or more PD-L1 expression in October, and the new data suggests its label could be updated to support more widespread use.

Merck - which is known as MSD outside the US - said it would file for approval of new labelling for Keytruda based on the data in the US and Europe in the coming weeks.

Opdivo brought in $305m to BMS' revenues in the third-quarter, ahead of Keytruda's $160m, with year-to-date sales for the two drugs at $467m and $352m respectively.

Article by
Phil Taylor

22nd December 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...